President's overview of ASCO 2012

Changing the standard treatment for lymphoma with bendamustine

Bendamustine regimen more effective for lymphoma than standard CHOP

Relapse and survival of adolescent and young adult leukaemia patients

Ibrutinib induces responses in aggressive lymphomas

Recent advances in multiple myeloma therapy

Recent advances in non-Hodgkin’s lymphoma therapy

BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma

Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell non-hodgkin lymphoma (GAUSS)

ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma

Two rituximab dosing strategies for low tumour burden follicular lymphoma (RESORT)

Cereblon expression required for anti-myeloma activity of lenalidomide and pomalidomide